Generating, Evaluating, and Implementing Evidence for Drug-Drug Interactions in H

描述(由申请人提供)：会议标题：在卫生信息技术中产生、评估和整合药物-药物相互作用的证据，以改善患者安全：一个多方利益相关者会议。尽管卫生信息技术取得了重大进步，但每年仍有数百万患者暴露在可预防的药物-药物相互作用(DDIS)中。这在很大程度上是由于系统设计问题以及DDI证据库。这项提案要求部分支持将于2009年10月13日和14日在马里兰州罗克维尔的卫生保健研究和质量机构(AHRQ)总部举行的关于DDIS证据和证据使用的多方利益攸关方会议。会议的广泛和长期目标是改善DDI证据基础，以及如何利用它来最终减少这些可预防的用药差错的发生。在这次会议上，将讨论目前DDI证据基础和临床决策支持方面的问题。将制定战略，以允许对DDI文献进行一致的评估，并改进DDI证据和临床决策辅助工具的实际效用。会议的具体目标是：1)制定评估和改进DDI证据基础的方法；2)设计机制，通过健康信息向提供者和消费者传达DDIS的证据 3)制定和传播评估和改进DDIS证据的建议，并将这些信息纳入卫生信息技术。预计将有100名与会者，包括发言者和主持人，参加为期一天半的会议。演讲者和主持人代表了DDI药典、药学软件、证据和临床决策支持的主要专家和开发人员。参与者代表利益相关者，例如：1) 消费者；2)个人医疗保健提供者；3)负责重要政策和指南、标准、支付、监管和认证的人；4)负责提供保健服务的组织；以及5)行业，如DDI药典、数据库、临床决策支持系统和制药业的开发商。DDIS造成的危害的确切程度尚不清楚，但迄今进行的研究表明，这是一个重大的公共卫生问题。最重要的是，它们是可以预防的医疗差错。早就应该召开一次会议，让利益相关者一起评估、讨论和提出改进DDI证据使用的方法，特别是在联邦政府推出电子处方的情况下。由于缺乏一个现有的论坛来讨论有助于DDIS的具体问题，因此加强了本次会议的意义。改进DDI证据的生成、评估和集成到用于电子处方和药房系统的临床决策支持中，将最大限度地减少警报疲劳，并最终提高患者的安全性，从而最大限度地发挥这些技术的价值。

DESCRIPTION (PROVIDED BY APPLICANT): Conference Title: Generating, Evaluating, and Integrating Evidence for Drug-Drug Interactions in Health Information Technology to Improve Patient Safety: A Multi Stakeholder Conference. Despite significant advances in health information technology, millions of patients are exposed to preventable drug-drug interactions (DDIs) each year. This is largely due to system design issues as well as the DDI evidence base. This proposal requests partial support for a multi stakeholder conference on the evidence and use of that evidence for DDIs to be held at the Agency for Health Care Research and Quality (AHRQ) headquarters in Rockville, Maryland on October 13 and 14, 2009. The broad and long term goal of the conference is to improve the DDI evidence base and how it is utilized to ultimately decrease the occurrence of these preventable medication errors. At this conference, current problems with the DDI evidence base and clinical decision support will be discussed. Strategies will be developed to allow for consistent evaluation of the DDI literature and improvement in the practical utility of DDI evidence and clinical decision aids. Specific aims of the conference are to: 1) formulate methods to evaluate and improve the DDI evidence base; 2) design mechanisms to communicate evidence for DDIs to providers and consumers through health information technology; and 3) develop and disseminate recommendations for evaluating and improving the evidence for DDIs and integrating this information into health information technology. An estimated 100 participants including speakers and moderators will attend the one and one half day conference. The speakers and moderators represent key experts and developers of DDI compendia, pharmacy software, evidence, and clinical decision support. The participants represent stakeholders such as: 1) consumers; 2) Individual health care providers; 3) Those responsible for salient policy and guidelines, standards, payment, regulation, and accreditation; 4) Organizations responsible for delivering care; and 5) industry, such as developers of DDI compendia, databases, and clinical decision support systems and pharmaceutical industry. The exact magnitude of harm induced by DDIs is unknown, but research conducted to date suggests that this topic is a large public health issue. Most importantly, they are preventable medical errors. A conference that brings together stakeholders to evaluate, discuss, and propose methods to improve the use of DDI evidence is long overdue, especially with the federal government's initiatives for electronic prescribing. The lack of an existing forum to discuss specific issues contributing to DDIs enhances the significance of this conference. Improving the generation, evaluation, and integration of DDI evidence into clinical decision support utilized for electronic prescribing and pharmacy systems will maximize the value of these technologies by minimizing alert fatigue and ultimately improving patient safety.